<DOC>
	<DOCNO>NCT02964988</DOCNO>
	<brief_summary>The purpose study investigate applicability urokinase plasminogen activator receptor ( uPAR ) Positron Emission Tomography ( PET ) / CT molecular imaging patient metastatic castration-resistant prostate cancer ( mCRPC )</brief_summary>
	<brief_title>uPAR PET/CT Radium-223-dichloride Treatment Patients With Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description>68Ga-NOTA-AE105 radioligand target urokinase plasminogen activator receptor ( uPAR ) , promise image biomarker tumor aggressiveness . 68Ga-NOTA-AE105 PET/CT apply patient mCRPC treatment Radium-223 . PET/CT perform initiation Radium therapy two treatment cycle . The initial semiquantitative uptake ( standard uptake value , SUVs ) 68Ga-NOTA-AE105 metastasis well change parameter therapy correlate overall survival progression free survival .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Metastatic castration resistant prostate cancer Approved receive Radium223 therapy Written oral consent Lack communication skills Other know malignant disease Known allergy towards IMP Severe claustrophobia If participant exhibit allergic reaction IMP , participant exclude participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>